



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

产品名称: VER 49009  
产品别名: CCT 129397; VER-49009

生物活性:				
Description	VER-49009 is a Hsp90 inhibitor, with an IC <sub>50</sub> of 25 nM and a K <sub>d</sub> of 78 nM.			
IC <sub>50</sub> & Target	HSP90			
	25 nM (IC <sub>50</sub> )			
In Vitro	VER-49009 is a Hsp90 inhibitor, with an IC <sub>50</sub> of 25 nM. VER-49009 binds to the ATPase of full length yeast Hsp90 protein, with an IC <sub>50</sub> of 140 nM[1]. VER-49009 inhibits Hsp90, with a K <sub>d</sub> of 78 nM. VER-49009 also shows antiproliferative activities against various human cancer cells, with a mean GI <sub>50</sub> of 685 ± 119 nM. VER-49009 suppresses the proliferation of human umbilical vein endothelial cells (HUVEC) with GI <sub>50</sub> values of 444 ± 91.1 nM, and shows higher GI <sub>50</sub> s against nontumorigenic human breast (MCF10a) and prostate (PNT2) epithelial cells. VER-49009 displays no differences in cellular activities of isogenic cell lines, and these activities are independent of NQO1 expression[2]. VER-49009 inhibits the proliferation (1, 2.5 μM), induces G2 phase arrest and reduces total Akt and phospho-Akt expression levels in CFSC cells (1-5 μM)[3].			
In Vivo	VER-49009 (4 mg/kg, i.p.) results in clear depletion of ERBB2 at 3 and 8 h following the final dose, with client protein levels returning to normal by 24 h, in the athymic mice bearing well-established OVCAR3 human ovarian ascites tumors[2].			
Solvent&Solubility	<b>In Vitro:</b> DMSO : 100 mg/mL (257.85 mM; Need ultrasonic) H <sub>2</sub> O : < 0.1 mg/mL (insoluble)			
	<div>Preparing Stock Solutions</div>	<div>Solvent Mass Concentration</div>	1 mg	5 mg
		1 mM	2.5785 mL	12.8926 mL
		5 mM	0.5157 mL	2.5785 mL
		10 mM	0.2579 mL	1.2893 mL
	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month。-80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。 <b>In Vivo:</b> 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液, 再依次添加助溶剂: ——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存; 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶 1.请依序添加每种溶剂: 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline Solubility: ≥ 2.75 mg/mL (7.09 mM); Clear solution 此方案可获得 ≥ 2.75 mg/mL (7.09 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例, 取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中, 混合均匀。			



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

	<p>向上述体系中加入 50 <math>\mu</math>L Tween-80, 混合均匀; 然后继续加入 450 <math>\mu</math>L 生理盐水定容至 1 mL。</p> <p>2. 请依序添加每种溶剂: 10% DMSO <math>\rightarrow</math> 90% corn oil</p> <p>Solubility: <math>\geq 2.75</math> mg/mL (7.09 mM); Clear solution</p> <p>此方案可获得 <math>\geq 2.75</math> mg/mL (7.09 mM, 饱和度未知) 的澄清溶液, 此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例, 取 100 <math>\mu</math>L 27.5 mg/mL 的澄清 DMSO 储备液加到 900 <math>\mu</math>L 玉米油中, 混合均匀。</p>
References	<p>[1]. Dymock BW, et al. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem. 2005 Jun 30;48(13):4212-5.</p> <p>[2]. Sharp SY, et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinyl pyrazole/isoxazole amide analogues. Mol Cancer Ther. 2007 Apr;6(4):1198-211.</p> <p>[3]. Sun X, et al. Inhibition of hepatic stellate cell proliferation by heat shock protein 90 inhibitors in vitro. Mol Cell Biochem. 2009 Oct;330(1-2):181-5.</p>
实验参考:	
Cell Assay	<p>Briefly, <math>5 \times 10^3</math> cells/well are plated in 96-well culture plates. After an overnight incubation, the cells are treated with various concentrations of VER-49009 and VER-49009M (0, 1, 2.5, and 5 <math>\mu</math>M) for 24 h[3].</p>
Animal Administration	<p>In some studies, female NCr athymic mice are implanted i.p. with 10 million OVCAR3 ovarian carcinoma cells harvested from donor mice. This tumor mimics late-stage malignant disease. Once tumors are well established, mice are injected i.p. with 4 mg/kg VER-49009 or VER-50589 twice daily over 2 days (four doses total). Tumors are harvested at intervals after the last dose and snap frozen for pharmacodynamic analyses[1].</p>
References	<p>[1]. Dymock BW, et al. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem. 2005 Jun 30;48(13):4212-5.</p> <p>[2]. Sharp SY, et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinyl pyrazole/isoxazole amide analogues. Mol Cancer Ther. 2007 Apr;6(4):1198-211.</p> <p>[3]. Sun X, et al. Inhibition of hepatic stellate cell proliferation by heat shock protein 90 inhibitors in vitro. Mol Cell Biochem. 2009 Oct;330(1-2):181-5.</p>